Chat
Feedback
Settings

Settings

Goto Application

5,622 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:(A61B1/00 OR A61B3/00 OR A61B5/00 OR A61B6/00 OR A61B7/00 OR A61B8/00 OR A61B9/00 OR A61B10/00 OR A61B13/00 OR A61B16/00) AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 563
1.20210304408Assessment of abnormality regions associated with a disease from chest CT images
US - 30.09.2021
Int.Class G06T 7/00
GPHYSICS
06COMPUTING; CALCULATING OR COUNTING
TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
7Image analysis
 Appl.No 16837979 Applicant Siemens Healthcare GmbH Inventor Shikha Chaganti

Systems and methods for assessing a disease are provided. Medical imaging data of lungs of a patient is received. The lungs are segmented from the medical imaging data and abnormality regions associated with a disease are segmented from the medical imaging data. An assessment of the disease is determined based on the segmented lungs and the segmented abnormality regions. The disease may be COVID-19 (coronavirus disease 2019) or diseases, such as, e.g., SARS (severe acute respiratory syndrome), MERS (Middle East respiratory syndrome), or other types of viral and non-viral pneumonia.

2.WO/2021/247682METHODS FOR MITIGATING OR DIMINISHING SPREAD OF PATHOGENIC INFECTIONS
WO - 09.12.2021
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
 Appl.No PCT/US2021/035421 Applicant ROSS, Peter M. Inventor ROSS, Peter M.
The present methods comprise initial administration of a first rapid test, such as rapid antigen test, that has a low likelihood of false positive results and a known likelihood of false negative results, alone or in conjunction with other rapid tests, to identify a first subpopulation of positives, to which an infection mitigation protocol (such as quarantine or the administration of a therapeutic treatment) is administered. Negatives are recorded and provisionally released from further study. A diagnostic test is then administered to this subpopulation, to identify the portion of this first subpopulation that were false positives in the first test. Ideally, a positive result for the diagnostic test is pathognomonic for the infection. Any infection mitigation protocol (such as quarantine) may then be discontinued for those testing negative in the first population and intensified for those testing positive, such as with contact tracing or other protocols, to identify all true positives and those they may have infected within the population.
3.WO/2022/191742A METHOD FOR ASSESSMENT OF THE CELLULAR IMMUNE
WO - 15.09.2022
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
 Appl.No PCT/RU2022/050074 Applicant DUKHOVLINOV, Ilya Vladimirovich Inventor DUKHOVLINOV, Ilya Vladimirovich
An invention relates to medicine, molecular biology, pharmaceuticals and can be used for the diagnostics of immunity to coronavirus infection. A method for assessment of the cellular immune response against coronavirus infection is proposed, consisting in intradermal administration of coronavirus antigen preparation and visual assessment of the skin reaction at the injection site after 24-96 hours. The advantages are a simplicity of implementation – the analysis can be carried out on an outpatient basis, for example, in a state-funded health center by a nurse, as well as a high specificity and sensitivity of the method. The method can be used for a massive, fast and cheap assessment of specific cellular immunity against SARS-CoV-2 coronavirus without a special equipment.
4.20210315461Methods of diagnosing and treating viral infections
US - 14.10.2021
Int.Class A61B 5/01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
01Measuring temperature of body parts
 Appl.No 17229185 Applicant Ibrahim Saud Almishari Inventor Ibrahim Saud Almishari

Diagnosing and treating viral infections. One example is a method of diagnosing absence of severe acute respiratory syndrome 2 (SARS-CoV-2), the method including: isolating a human in a covid-free environment for an isolation period; performing measurements of a core temperature during the isolation period; and if each of the measurements of the core temperature indicate a lack of fever, declaring the human free of SARS-CoV-2. Another example is a method including treating coronavirus in a human by: receiving a core temperature measurement; receiving a test result regarding the SARS-CoV-2 virus; responsive to the human having both fever and the presence of the SARS-CoV-2 virus, submerging the trunk and the legs of the human in water with a surfactant, and the human at least partially submerged for a treatment period of at least three hours; and controlling a temperature of the water during the treatment period.

5.WO/2022/177466THE USE OF THE AGENT FOR INDUCING IMMUNITY TO SARS-COV-2
WO - 25.08.2022
Int.Class G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
 Appl.No PCT/RU2022/000046 Applicant FEDERAL STATE BUDGETARY INSTITUTION "NATIONAL RESEARCH CENTER FOR EPIDEMIOLOGY AND MICROBIOLOGY NAMED AFTER THE HONORARY ACADEMICIAN N.F. GAMALEYA" OF THE MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION Inventor ZUBKOVA, Olga Vadimovna
Group of invention relates to biotechnology, immunology and virology. Described is the use of an agent containing expression vector based on strain human adenovirus serotype 26 or human adenovirus serotype 5, in which E1 and E3 regions are deleted, with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or simian adenovirus serotype 25, in which E1 and E3 regions are deleted with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 or contains only component 2 for providing prolongation of post-vaccination immunity against SARS-CoV-2. Also an agent can containing any two of said components. The group of inventions allows producing safe and effective agents providing prolongation of post-vaccination immunity against SARS-CoV-2 and is aimed at population revaccination against severe acute respiratory syndrome SARS-CoV-2.
6.WO/2024/036192COMPOSITIONS AND METHODS FOR ASSESSING THE SEVERITY OF AND TREATING COVID-19
WO - 15.02.2024
Int.Class C12Q 1/6827
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6813Hybridisation assays
6827for detection of mutation or polymorphism
 Appl.No PCT/US2023/071902 Applicant THE JOHNS HOPKINS UNIVERSITY Inventor JOHNS, Roger
The present invention relates to the field of virology. More specifically, the present invention provides compositions and methods for assessing the severity of and treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19. In particular embodiments, a method for treating COVID-19 in a patient comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.
7.WO/2022/256741SENSOR FOR DETECTING BIOMARKERS IN A FLUID SAMPLE AND METHODS OF USE
WO - 08.12.2022
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
 Appl.No PCT/US2022/032379 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY Inventor MUTHUSWAMY, Jitendran
The invention relates to a diagnostic platform for detection of biomarkers associated with a particular condition, disease, or disorder and methods of making and using the same. In various embodiments, the diagnostic platform includes a sensing device and an electronic reading platform. Aspects of the invention are directed to a diagnostic platform for detection of at least one biomarker in a fluid sample. In embodiments, the diagnostic platform comprises a sensing device configured to receive the fluid sample. The platform can further comprise an electronic reading platform and a computing device. The electronic reading platform can be configured to activate the sensor.
8.WO/2022/159886BIOLOGICS DETECTION DEVICE
WO - 28.07.2022
Int.Class G06T 7/00
GPHYSICS
06COMPUTING; CALCULATING OR COUNTING
TIMAGE DATA PROCESSING OR GENERATION, IN GENERAL
7Image analysis
 Appl.No PCT/US2022/013690 Applicant ADVANCED MEDICAL SOLUTIONS INTERNATIONAL, LLC Inventor SAID, Nassar, O.
Methods and apparatus for non-invasively and accurately detecting a chemically- stable molecular structure. The methods and apparatus can be used to detect molecules associated with disease and disorders, and objects or subjects associated with such disease and disorders, such as contaminated with the molecules or pathogens, or having disease or disorder associated with the molecules or pathogens.
9.20240055122METHODS, SYSTEMS AND RELATED ASPECTS FOR REAL-TIME PREDICTION OF ADVERSE OUTCOMES USING MACHINE LEARNING AND HIGH-DIMENSIONAL CLINICAL DATA
US - 15.02.2024
Int.Class G16H 50/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
20for computer-aided diagnosis, e.g. based on medical expert systems
 Appl.No 18257925 Applicant THE JOHNS HOPKINS UNIVERSITY Inventor Julie K. SHADE

Provided herein are methods of generating models for prognosing cardiovascular outcomes for monitored subjects infected with an etiologic agent (e.g., severe acute respiratory syndrome coronavirus-2 or another etiologic agent). Related methods, systems, and computer program products are also provided.

10.WO/2022/133258REAL-TIME PREDICTION OF ADVERSE OUTCOMES USING MACHINE LEARNING
WO - 23.06.2022
Int.Class A61B 5/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
02Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure
 Appl.No PCT/US2021/064106 Applicant THE JOHNS HOPKINS UNIVERSITY Inventor SHADE, Julie, K.
Provided herein are methods of generating models for prognosing cardiovascular outcomes for monitored subjects infected with an etiologic agent (e.g., severe acute respiratory syndrome coronavirus-2 or another etiologic agent). Related methods, systems, and computer program products are also provided.
# -